CATX

NYSEAMERICAN open

Perspective Therapeutics

0.75 USD
▼-0.04-4.57%
盘后 0.79 0.00%
2026-11-20
市值
$91.03M
市盈率
—
EPS
-1.17
股息率
—
52 周区间
0.73 – 6.16
成交量
820.68K
Beta
1.99
目标价
9.43
52W 低 0.7352W 高 6.16
价格走势

公司简介

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2...